NCT01449747View on ClinicalTrials.gov

Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

August 31, 2014

Study Completion Date

July 31, 2015

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Sitagliptin

Sitagliptin (100mg, per oral) once a day.

Trial Locations (2)

130-709

The Catholic University of Korea; St.Paul's Hospital, Seoul

137-701

The Catholic University of Korea; Seoul St. Mary's Hospital, Seoul

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

The Catholic University of Korea

OTHER

NCT01449747 - Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter